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Abstract
Background:  Myeloperoxidase (MPO) -containing macrophages and neutrophils have been
described at sites of plaque rupture. The presence of these cells in precursor lesions to acute
rupture (thin cap atheroma, or vulnerable plaque) and within thrombi adjacent to ruptures has not
been described, nor an association with iron-containing macrophages within unstable plaques.
Methods: We studied 61 acute ruptures, 15 organizing ruptures, 31 thin cap fibroatheromas, and
28 fibroatheromas from 72 sudden coronary death victims by immunohistochemical and
histochemical techniques. Inflammatory cells were typed with anti-CD68 (macrophages), anti-BP-
30 (neutrophil bactericidal glycoprotein), and anti-MPO. Iron was localized by Mallory's Prussian
blue stain. In selected plaques alpha smooth muscle actin (DAKO, Carpinteria, CA, clone M0851)
was performed.
Results: MPO positive cells were present in 79% of ruptured caps, 28% of thin cap fibroatheroma,
and no fibroatheromas; neutrophils were present in 72% of ruptures, 8% of thin cap
fibroatheromas, and no fibroatheromas. Iron containing foam cells were present in the caps of 93%
of acute ruptures, of 85% of organizing ruptures, 20% of thin cap atheromas, and 10% of
fibroatheromas. MPO positive cells were more frequent in occlusive than non-occlusive thrombi
adjacent to ruptures (p = .006) and were more numerous in diabetics compared to non-diabetics
(p = .002)
Conclusion: Unstable fibrous caps are more likely to contain MPO-positive cells, neutrophils, and
iron-containing macrophages than fibrous caps of stable fibroatheromas. MPO-positive cells in
thrombi adjacent to disrupted plaques are associated with occlusive thrombi and are more
numerous in diabetic patients.
Background
Plaque rupture is a major cause of coronary thrombosis,
and is morphologically characterized by an interruption
in a thin fibrous cap overlying a lipid rich core. [1-4]
Often there are numerous macrophages infiltrating the
fibrous cap of rupture plaques, suggesting a critical role in
inciting plaque rupture. More recently, myeloperoxidase
(MPO) expressing monocytes and neutrophils have been
described at the site of plaque disruption, suggesting a
role of MPO in plaque rupture. [5,6] However, the precise
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factor precipitating plaque rupture, as well as the morpho-
logic and cellular differences that identify a vulnerable
plaque (thin cap fibroatheroma) prone to rupture are cur-
rently not known.
Circulating monocytes produce hypochlorous acid by
activation of MPO, increasing oxidative stress. [7,8]
Recent evidence suggests that MPO-producing macro-
phages may persist in the atherosclerotic plaque and con-
tribute to plaque instability. [9] In addition, serum levels
of MPO seem to correlate with adverse risks in acute cor-
onary syndrome patients.[10]
The purpose of this study was threefold: (1) to corrobo-
rate Sugiyama et al's and Naruko's finding that MPO pos-
itive cells including neutrophils are increased at the site of
plaque instability; [5,6] (2) to quantitate MPO positive
cells and neutrophils for the first time in thin-cap
fibroatheroma; and (3) to correlate numbers of MPO pos-
itive cells in thrombi adjacent to ruptures with thrombus
characteristics and risk factors.
Methods
Autopsy sections of coronary artery plaques were selected
from patients dying with severe coronary atherosclerosis.
Inclusion for study included apparent natural cardiac
deaths at the time of autopsy, with drug-related deaths
subsequently excluded in cases of positive toxicology.
Cases were seen in consultation at the Armed Forces Insti-
tute of Pathology from the Office of the Chief Medical
Examiner in Baltimore, Maryland, under institutional
review board approval. Hearts with severe coronary artery
disease (≥ 75% cross section luminal narrowing of ≥ 1 epi-
cardial artery) were included for study. Sections selected
for study included 135 sections from 72 patients, namely
28 fibroatheromas, 31 thin-cap fibroatheromas, 61 acute
plaque ruptures, 15 healing plaque ruptures. Plaque types
were defined as previously described [11-16].
The distribution of lesions per arterial segment is pre-
sented on Table 1. Healing rupture denoted areas of acute
thrombus overlying plaque disruption, with endothelial
cell organization of portion of the fibrin thrombus with
persistence of fibrin within the thrombus. [12]. Risk fac-
tors were determined by clinical history obtained from
investigators and by serum corroboration when necessary.
No cases of intra-coronary intervention were included in
the study.
Immunohistochemical inflammatory markers studied
were CD68 (KP1 clone, Dako, Carpinteria, CA, dilution
1:50, pan-macrophage marker), BP 30/Cathepsin G (R &
D Systems, Minneapolis, 1:80, neutrophil marker), and
MPO (Biodesign, Kennebunk ME, dilution 1:250). Iron
stain was performed using standard Perls modification of
Mallory Prussian blue iron histochemical stain. In
selected plaques alpha smooth muscle actin (DAKO,
Carpinteria, CA, clone M0851) was performed at 1:400
dilution. Quantitation of cellular elements was performed
in the fibrous cap region by computerized morphometric
measurements (IPLab SpectrumTM image processing soft-
ware, Signal Analytics Corporation, Vienna, VA). Compar-
isons of two means was performed using Student's T test,
and of multiple categories was performed using ANOVA
means table with Fisher's post hoc testing. Non-paramet-
ric comparison was performed using Mann-Whitney com-
parison means testing. Statistical analysis was performed
using SAS software (Cary, NC).
Results
The patient age ranged from 37 to 82 (mean, 52 years),
and there were 66 male and 6 females patients. Seventy-
three percent were white and 26% black. The heart
weights ranged from 204 to 875 (mean 511 g). Risk fac-
tors included 10 diabetic patients, 22 hypertensive, 37
hypercholesterolemic and 36 smokers. There were no sta-
tistical differences between the three groups (acute rup-
ture, healing rupture, stable plaque) in regards to sex, age,
Table 1: Distribution of lesions by arterial segment
Arterial segment Acute ruptures (n = 61) Healing ruptures (n = 15) Thin cap fibroatheroma (n = 31) Stable plaques (n = 27)
Left main 2 0 0 0
Proximal LAD 16 5 6 10
Mid LAD 8 0 2 2
Distal LAD 0 0 1 1
Left diagonal 0 0 1 0
Left circumflex 13 2 3 4
Obtuse marginal 1 1 1 1
Proximal RC 8 2 8 6
Mid RC 7 5 5 2
Distal RC 5 0 2 1
PDA 1 0 2 0
LAD = left anterior descending; LOM = left obtuse marginal; RC right coronary; PDA = posterior descendingBMC Cardiovascular Disorders 2009, 9:27 http://www.biomedcentral.com/1471-2261/9/27
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gender, or heart weight (Table 2). Risk factors and demo-
graphic data are presented in Table 2, as well as distribu-
tion of sampled plaque types by culprit plaque
morphology. Of the 72 patients, culprit plaques were 51
acute ruptures (Figures 1 and 2), 5 healing ruptures, and
16 stable plaques without plaque disruption. The plaques
sampled were 61 ruptures, 15 healing ruptures, 31 thin
cap fibroatheromas, and 28 fibroatheromas with thick
caps.
Table 3 demonstrates the density of macrophages (identi-
fied by CD 68 immunostaining), neutrophils (identified
by cathepsin G immunostaining), MPO containing mac-
rophages/neutrophils (Figures 3 and 4), and iron-contain-
ing macrophages within the fibrous caps of
fibroatheromas, thin cap fibroatheromas, and acute and
healing ruptures.
There was significant increase in macrophages in thin cap
fibroatheromas, ruptures, and healing ruptures vs.
fibroatheromas (p < .0001). No fibroatheroma had int-
racap neutrophils, vs. 8% of thin cap fibroatheromas,
79% of acute ruptures, and 35% of healing ruptures (p <
.0001). There was no difference in intracap MPO positive
macrophages or neutrophils between thin cap fibroath-
eromas with culprit plaque acute ruptures as compared to
stable plaque. MPO cells were absent in fibroatheromas,
but present in 28% of thin cap fibroatheromas, 79% of
ruptures, and 60% of healing ruptures (p < .0001). Iron
containing macrophages were present similarly more fre-
quently in acute and healing ruptures than fibroathero-
mas and thin cap fibroatheromas (p < .0001).
Occlusive thrombi were longer than non-occlusive (Table
4), although there was no difference in length of necrotic
core. Density of cap MPO macrophages/neutrophils did
not differ between occlusive and non-occlusive thrombi;
however, adjacent thrombus had a higher concentration
of MPO and CD68 macrophages than non-occlusive
thrombi (p < .01, Table 4). Density of intracap macro-
phages overlying disrupted plaques (acute or organizing
ruptures) did not vary by risk factor; however, the density
of MPO positive cells was greater in diabetics with border-
line significance for smokers (Table 5). Acute ruptures
characterized by thin caps without actin positive cells, var-
iable numbers of actin positive smooth muscle cells at the
base of the plaque towards the internal elastic laminae
(IEL). Healing ruptures, the rupture site characterized by
fibrin, granulation tissue and none to few actin positive
cells, again variable numbers of actin positive smooth
muscle cells at the base of the plaque towards the IEL. In
thin cap fibroatheromas, the cap itself contained no
smooth muscle cells, but there were variable numbers of
actin positive smooth muscle cells at the base of the
plaque towards the IEL."
Discussion
The current study corroborates work by others, showing
increased MPO-containing cells and neutrophils in
plaque rupture sites. [5,6] It reveals new information
regarding MPO content comparing plaque subtype, espe-
cially small numbers in thin cap atheroma. MPO co-local-
izes with iron containing macrophages on the surface and
its density in thrombotic lesions correlates well with
thrombus size. The numbers of MPO containing cells are
also significantly higher in patients with diabetes and
Table 2: Patient demographics, 135 plaques from 72 sudden coronary deaths
Culprit plaque Totals
Acute rupture Healing rupture Stable plaque
N5 1 5 1 6 7 2
Age, years ± SD 52 ± 11 52 ± 10 48 ± 8 51 ± 11
Men: women 47:4 5:0 14:2 66:6
White:Black 38:13 3:2 12:4 53:19
Heart weight, g ± SD 504 ± 127 605 ± 125 466 ± 87 511 ± 134
Diabetic 9 0 1 10
Hypertensive 13 4 5 22
Hypercholesterolemic 25 3 9 37
Smokers 26 3 7 36
Number of plaques studied 100* 7 28 135
Acute ruptures 61 0 0 61
Healing ruptures 8 0 0 15
Thin cap FA 20 7 11 31
FA 11 0 17 28
FA = fibroatheroma
* in 10 hearts, 2 rupture sites > 3 mm separated were sampledBMC Cardiovascular Disorders 2009, 9:27 http://www.biomedcentral.com/1471-2261/9/27
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smoking history, creating a link between risk factors and
histomorphological findings.
MPO has emerged as a potential participant in the promo-
tion of atherosclerosis. [17] It is stored and secreted from
activated neutrophils and monocytes, and is an important
component in degranulation material of leukocytes, criti-
cal in human innate host defenses. [5,6] The MPO role in
atherosclerosis initiation and propagation is related to its
Acute plaque rupture with iron-containing macrophages at  the rupture site Figure 1
Acute plaque rupture with iron-containing macro-
phages at the rupture site. A. Low magnification of 
plaque rupture with occlusive thrombus. Movat penta-
chrome. B. Higher magnification of A showing rupture site 
demonstrating fragmented cap (top) and thrombus below. C. 
Perl's iron stain of the same area as B, demonstrating a large 
number of hemosiderin-laden macrophages at the rupture 
site.
Acute plaque rupture with iron-containing macrophages at  the rupture site Figure 2
Acute plaque rupture with iron-containing macro-
phages at the rupture site. A. Low magnification of 
plaque rupture with occlusive thrombus. Movat penta-
chrome. B. Higher magnification of A showing rupture site 
with prominent cholesterol crystals. C. Perl's iron stain, low 
magnification demonstrating hemosiderin-laden macrophages 
at the rupture site (arrow), seen at higher magnification in D.
Table 3: Inflammatory infiltrates, fibrous cap
Cap type Macro-phages/
mm2
% with any 
neutro-phils
Neutro-phils/
mm2
% with any MPO 
+ cells
MPO + cells/
mm2
% with any iron + 
macro-phages
Iron + macro-
phages/mm2
Thick fibrous cap 
(fibro-atheroma, 
n = 28)
1 4 9  ±  1 9 9 00001 0 1 . 2
Thin cap 
(n = 31)
399 ± 238 8 2 ± 2 28 13 ± 5 32 20 ± 13
Rupture 
(n = 61)
416 ± 287 79 72 ± 22 79 117 ± 22 93 88 ± 44
Healing rupture 
(n = 15)
304 ± 269 35 5 ± 5 60 47 ± 20 85 90 ± 41
P value* P < .0001 P < .0001 P = .001 P < .0001 P < .0001 P < .0001 P < .0001
* ANOVA means table with Fisher's post-hoc testingBMC Cardiovascular Disorders 2009, 9:27 http://www.biomedcentral.com/1471-2261/9/27
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potential to activate lipid peroxidation and promoting
post-translational modification of target proteins.[18,19]
MPO catalyzes LDL oxidation and releases HOCl, degrad-
ing extracellular matrix. Recent studies have found that
MPO is capable of promoting oxidation of lipoproteins
which could lead to the increase in cholesterol deposit
and formation of foam cells in fatty streaks.[18,20]
Tissue localization of MPO has been described in a variety
of inflammatory conditions,[19] MPO was found to be
increased in human atheromas more than a decade
ago.[21] More recently, studies have focused on the pres-
ence of MPO not only in early lesions, but also in acute
complications of atherosclerosis and plaque vulnerabil-
ity.[9] The link between MPO levels and CAD is strongly
supported by epidemiological studies. Individuals who
have high MPO levels are more likely to demonstrate
abnormal coronary angiograms compared to con-
trols.[22] Individuals with MPO deficiency have some
protection against CAD and others harboring a polymor-
phism that decreases MPO expression have markedly
reduced rates of CAD, myocardial infarction and cardiac
death. [23-25]
The current study corroborates the findings of Naruko et
al who analyzed 126 coronary sections using immunohis-
tochemical studies for macrophages (CD66b), neu-
MPO positive cells in the rupture site thrombus Figure 4
MPO positive cells in the rupture site thrombus. A 
demonstrates a low magnification of rupture of a large 
necrotic core. The arrow is the rupture site shown at higher 
magnification at B, which shows the fibrous cap (fc) above a 
thrombus rich in MPO-positive cells (immunohistochemical 
stain for myeloperoxidase). C is a slightly higher magnifica-
tion demonstrating the thrombus (thr) just adjacent to the 
torn fibrous cap.
Table 4: Plaque ruptures: Inflammatory cell density, luminal thrombi, and correlation with necrotic core characteristics
Length, mm Core length, mm Thrombus MPO + 
cell density/mm2
Thrombus CD68 
macro-phage density/
mm2
Cap MPO + cell 
density/mm2
Cap CD68 macro-
phage density/mm2
Occlusive 8.3 ± 4.2 8.9 ± 5.1 366 ± 80 424 ± 119 164 ± 85 352 ± 132
Non-occlusive 2.9 ± 2.4 9.3 ± 6.6 45 ± 32 83 ± 72 26 ± 11 540 ± 173
P value .01 0.9 .006 .004 .2 .4
MPO positive cells and neutrophils proximal to and at acute  rupture sites Figure 3
MPO positive cells and neutrophils proximal to and 
at acute rupture sites. A. 3 mm proximal to an acute rup-
ture site there were only scattered MPO-positive macro-
phages at the luminal surface. B. The rupture site 
demonstrates numerous MPO positive cells. C and D are 
corresponding images of the sites of A and B, respectively, 
demonstrating that many of the MPO positive cells express 
cathepsin G, a neutrophil marker.BMC Cardiovascular Disorders 2009, 9:27 http://www.biomedcentral.com/1471-2261/9/27
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trophils (CD11b) and myeloperoxidase. [5] The
population in their study was composed of material from
autopsies and atherectomy procedures. In the control of
patients dying form non-cardiac deaths, MPO was not
indentified in any case, whereas ruptured or eroded
plaques had MPO positivity mostly in neutrophils, and
only occasionally in macrophages. A similar approach
was used by Sugiyama et al, who found increased num-
bers of MPO-containing macrophages in eroded and rup-
tured plaques, with little to no MPO in fatty streaks. The
expression of MPO was also variably dependent on the
stage of atherosclerotic lesions, with special high expres-
sion with fibrous caps and activated plaques. [6] Our find-
ing of higher MPO expression in patients with diabetes
substantiates clinical studies that measured MPO in
plasma of diabetic patients versus controls. [26,27]
It is known that free iron in the plasma catalyzes lipid per-
oxidation and this reaction has been involved in the
development of atherosclerosis in the way of hydroxyl
radical formation by neutrophils requiring exogenous
iron.[28] Iron is stored as either ferritin or hemosiderin.
Ferritin consists of an outer protein shell with iron com-
plexed within the core. It has been postulated that either
MPO or lactoferrin could inhibit the formation of the
hydroxyl radical upon neutrophil degranulation. Since it
can be seen by light microscopy as gold-brown granules
and is demonstrated by the Prussian blue stain, we
assessed positivity of iron containing cells in culprit
lesions and found that these were more frequently present
in acute and healing ruptures than fibroatheromas and
thin cap fibroatheromas. Although the molecular rela-
tionship between iron and myeloperoxidase is unknown,
MPO contains an iron porphyrin prosthetic group. In
other inflammatory conditions, such as asthma, there
seems to be an association between levels of MPO and
iron, and it is suggested they may act in a concerted man-
ner in the pathogenesis of the disease. [29] While our
findings of elevated iron and MPO do not elucidate its
possible mechanistic relationship, it brings new data to
the discussion of the pathogenesis of atherosclerosis pro-
gression.
Conclusion
MPO localizes in macrophages and neutrophils at the site
of plaque rupture, as has been previously demonstrated,
and only occasionally in precursor thin cap atheroma. A
causative association between MPO and rupture has not
been established but remains a possibility that requires
further study. Localization of iron at rupture sites is a
novel finding that may have implications for imaging of
unstable plaques. Whether there is a link between iron
deposits at rupture sites and MPO likewise remains an
area for investigation.
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